ArticleChemMedChem2026
Novel Inhibitors of Carbonic Anhydrase I and II Identified by High Throughput Virtual Screening and Validated by X-Ray Crystallography.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-throughput virtual screening (HTVS) enables rapid exploration of large chemical spaces to identify novel modulators of biologically relevant targets. In this study, we applied a large-scale docking campaign to discover new inhibitors of the human Carbonic Anhydrase isoforms I and II. Starting from library of 28,000 compounds, iterative Glide HTVS, SP, and XP docking against hCA I and hCA II yielded 81 top-ranked compounds for experimental evaluation. Among these, five compounds showed micromolar inhibition of hCA II, and one also inhibited hCA I. X-ray crystallographic studies of two carboxylate-based inhibitors (1 and 2) revealed distinct binding modes. Compound 1 directly coordinates the catalytic zinc ion, whereas compound 2 adopts two different binding poses: one anchored to the zinc-bound water molecule and another within a surface-accessible pocket near His64. The latter region, which modulates the proton-shuttling mechanism essential for catalysis, represents a less-explored site for inhibitor development. Overall, these findings validate our HTVS workflow and provide a foundation for the structure-guided optimization of carboxylate scaffolds as carbonic anhydrase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.